eplontersen: Clinical Trials

9 trials of eplontersen, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

5 completed, 3 active not recruiting, 1 enrolling by invitation. 5 Phase 3, 3 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	5	Active not recruiting 2, Completed 2, Enrolling by invitation 1
Phase 1	3	Completed 3
Phase 2	2	Active not recruiting 1, Completed 1

Follow eplontersen: new trials by email Literature Review of eplontersen trials Research Report on eplontersen

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM Eplontersen, ALXN2220, Placebo - Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	Phase 2	Active not recruiting	AstraZeneca	326	2026-06-11	2026-07-14
A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers Eplontersen Solution for Injection - Transthyretin-mediated Amyloidosis	Phase 1	Completed	AstraZeneca	12	2024-08-06	2024-11-21
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy Eplontersen, Placebo - Transthyretin Amyloid Cardiomyopathy	Phase 3	Active not recruiting	AstraZeneca	64	2023-12-01	2026-06-09
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Eplontersen - Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)	Phase 3	Enrolling by invitation	Ionis Pharmaceuticals, Inc.	1400	2022-11-30	2026-04-17
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Eplontersen - Hereditary Transthyretin-Mediated Amyloid Polyneuropathy	Phase 3	Active not recruiting	Ionis Pharmaceuticals, Inc.	151	2022-01-04	2025-12-04
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants Eplontersen, Placebo - Healthy Participants	Phase 1	Completed	Ionis Pharmaceuticals, Inc.	24	2020-04-23	2022-03-31
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) Eplontersen, Placebo - Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)	Phase 3	Completed	Ionis Pharmaceuticals, Inc.	1438	2020-03-13	2026-09-03
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Inotersen, Eplontersen - Hereditary Transthyretin-Mediated Amyloid Polyneuropathy	Phase 3	Completed	Ionis Pharmaceuticals, Inc.	168	2019-12-11	2024-12-13
Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ). ION-682884, Placebo, Vitamin A - Healthy Volunteers, hATTR Amyloidosis	Phase 1 / Phase 2	Completed	Ionis Pharmaceuticals, Inc.	47	2018-12-21	2022-12-19

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding